Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis

Abstract

Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.

Figure 1

Forest plots of network meta-analysis results of adults^a treated between 8 and 16 weeks for change in (a) Eczema Area and Severity Index (EASI), (b) Patient-Oriented Eczema Measure (POEM), (c) Dermatology Life Quality Index (DLQI) and (d) Peak Pruritus Numeric Rating Scale (PP-NRS). Results are presented as mean difference (MD) with 95% credible intervals (CrI) for selected currently available targeted medications vs. dupilumab 600 mg then 300 mg every 2 weeks. MDs > 0 indicate that the comparator is associated with more improvement than dupilumab. MDs < 0 indicate that the comparator is associated with less improvement than dupilumab. Results for the complete networks are available on request. Abrocitinib 100, abrocitinib 100 mg daily; Abrocitinib 200, abrocitinib 200 mg daily; Baricitinib 2, baricitinib 2 mg daily; Baricitinib 4, baricitinib 4 mg daily; Lebrikizumab, lebrikizumab 500 mg at weeks 0 and 2 then 250 mg every 2 weeks; Nemolizumab, nemolizumab 60 mg then 30 mg every 4 weeks; Tralokinumab, tralokinumab 600 mg then 300 mg every 2 weeks; Upadacitinib 15, upadacitinib 15 mg daily; Upadacitinib 30, upadacitinib 30 mg daily. ^aSome studies included in the analyses of trials of adults include a minority proportion of adolescent participants (12–17 years old).

Figure 1

Forest plots of network meta-analysis results of adults^a treated between 8 and 16 weeks for change in (a) Eczema Area and Severity Index (EASI), (b) Patient-Oriented Eczema Measure (POEM), (c) Dermatology Life Quality Index (DLQI) and (d) Peak Pruritus Numeric Rating Scale (PP-NRS). Results are presented as mean difference (MD) with 95% credible intervals (CrI) for selected currently available targeted medications vs. dupilumab 600 mg then 300 mg every 2 weeks. MDs > 0 indicate that the comparator is associated with more improvement than dupilumab. MDs < 0 indicate that the comparator is associated with less improvement than dupilumab. Results for the complete networks are available on request. Abrocitinib 100, abrocitinib 100 mg daily; Abrocitinib 200, abrocitinib 200 mg daily; Baricitinib 2, baricitinib 2 mg daily; Baricitinib 4, baricitinib 4 mg daily; Lebrikizumab, lebrikizumab 500 mg at weeks 0 and 2 then 250 mg every 2 weeks; Nemolizumab, nemolizumab 60 mg then 30 mg every 4 weeks; Tralokinumab, tralokinumab 600 mg then 300 mg every 2 weeks; Upadacitinib 15, upadacitinib 15 mg daily; Upadacitinib 30, upadacitinib 30 mg daily. ^aSome studies included in the analyses of trials of adults include a minority proportion of adolescent participants (12–17 years old).